Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 3
Submit an article Journal homepage
158
Views
19
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetic differences and drug–drug interactions in immunosuppressive therapy

Jill S Warrington Duke University Medical Center, Department of Pathology, Box 3712, Durham, NC 27710, USA
&
Leslie M Shaw University of Pennsylvania Medical Center, Department of Pathology and Laboratory Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA. [email protected]
Pages 487-503 | Published online: 29 Sep 2005

Bibliography

  • BARONE CP, MARTIN-WATSON AL, BARONE GW: The postoperative care of the adult renal transplant recipient. Medsurg. Nurs. (2004) 13(5):296–302; quiz 303.
  • HABERAL M, DALGIC A: New concepts in organ transplantation. Transplant. Proc. (2004) 36(5):1219–1224.
  • SMITH JM, MCDONALD RA: Renal transplantation in adolescents. Adolesc Med. Clin. (2005) 16(1):201–214.
  • MACDONALD A, SCAROLA J, BURKE JT, ZIMMERMAN JJ: Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin. Ther. (2000) 22(Suppl. B):B101–B121.
  • SHAW LM, KORECKA M, DENOFRIO D, BRAYMAN KL: Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin. Biochem. (2001) 34(1):17–22.
  • ANGLICHEAU D, LEGENDRE C, THERVET E: Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation (2004) 78(3):311–315.
  • CATTANEO D, PERICO N, REMUZZI G: From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am. J. Transplant. (2004) 4(3):299–310.
  • DEIERHOI MH, HAUG M 3rd: Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy. Clin. Transplant. (2000) 14(5):439–448.
  • ROSENBAUM SE, BAHETI G, TRULL AK, AKHLAGHI F: Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther. Drug Monit. (2005) 27(2):116–122.
  • AW MM, BROWN NW, ITSUKA T et al. : Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl. (2003) 9(4):383–388.
  • DIPCHAND AI, PIETRA B, MCCRINDLE BW, ROSEBROOK-BICKNELL HL, BOUCEK MM: Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J. Heart Lung Transplant. (2001) 20(10):1035–1043.
  • FILLER G, FOSTER J, BERARD R, MAI I, LEPAGE N: Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant. Proc. (2004) 36(5):1327–1331.
  • KIM JS, AVILES DH, SILVERSTEIN DM, LEBLANC PL, MATTI VEHASKARI V: Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr. Transplant. (2005) 9(2):162–169.
  • DEL MAR FERNANDEZ DE GATTA M, SANTOS-BUELGA D, DOMINGUEZ-GIL A, GARCIA MJ: Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. (2002) 41(2):115–135.
  • ETTENGER RB, GRIMM EM: Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am. J. Kidney Dis. (2001) 38(4 Suppl. 2): S22-S28.
  • OELLERICH M, ARMSTRONG VW, STREIT F, WEBER L, TONSHOFF B: Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin. Biochem. (2004) 37(6):424–428.
  • SINDHI R, WEBBER S, VENKATARAMANAN R et al. : Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation (2001) 72(5):851–855.
  • HOYER PF, ETTENGER R, KOVARIK JM et al. : Everolimus in pediatric de nova renal transplant patients. Transplantation (2003) 75(12):2082–2085.
  • RUMBO C, SHNEIDER BL, EMRE SH: Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. Pediatr Transplant. (2004) 8(6):571–575.
  • CHAPMAN JR, O’CONNELL PJ, BOVINGTON KJ, ALLEN RD: Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. Transplantation. (1996) 61(12):1699–1704.
  • MUNDA R, SCHROEDER TJ, PEDERSEN SA et al. : Cyclosporine pharmacokinetics in pancreas transplant recipients. Transplant. Proc. (1988) 20(2 Suppl. 2):487–490.
  • JOHNSON HJ, SWAN SK, HEIM-DUTHOY KL, NICHOLLS AJ, TSINA I, TARNOWSKI T: The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin. Pharmacol. Ther. (1998) 63(5):512–518.
  • KAPLAN B, MEIER-KRIESCHE HU, FRIEDMAN G et al. : The effect of renal insufficiency on mycophenolic acid protein binding. J. Clin. Pharmacol. (1999) 39(7):715–720.
  • MEIER-KRIESCHE HU, SHAW LM, KORECKA M, KAPLAN B: Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther. Drug Monit. (2000) 22(1):27–30.
  • SHAW LM, MICK R, NOWAK I, KORECKA M, BRAYMAN KL: Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J. Clin. Pharmacol. (1998) 38(3):268–275.
  • WALKER S, HABIB S, ROSE M, YACOUB M, BANNER N: Clinical use and bioavailability of tacrolimus in heartlung and double lung transplant recipients with cystic fibrosis. Transplant. Proc. (1998) 30(4):1519–1520.
  • STAATZ CE, WILLIS C, TAYLOR PJ, TETT SE: Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin. Pharmacol. Ther. (2002) 72(6):660–669.
  • SIROLIMUS Rapamune oral solution (sirolimus). Wyeth-Ayerst Laboratories, Package insert, Princeton NJ, USA (1999).
  • KOVARIK JM, SABIA HD, FIGUEIREDO J et al. : Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin. Pharmacol. Ther. (2001) 70(5):425–430.
  • SCHUSZIARRA V, ZIEKURSCH V, SCHLAMP R, SIEMENSEN HC: Pharmacokinetics of azathioprine under haemodialysis. Int. J. Clin. Pharmacol. Biopharm. (1976) 14(4):298–302.
  • BISTRUP C, NIELSEN FT, JEPPESEN UE, DIEPERINK H: Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol. Dial. Transplant. (2001) 16(2):373–377.
  • DAHAN A, ALTMAN H: Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur. J. Clin. Nutr. (2004) 58(1):1–9.
  • DRESSER GK, SCHWARZ UI, WILKINSON GR, KIM RB: Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin. Pharmacol. Ther. (2003) 73(1):41–50.
  • TAN KK, TRULL AK, UTTRIDGE JA et al. : Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther. (1995) 57(4):425–433.
  • MAI I, STORMER E, BAUER S, KRUGER H, BUDDE K, ROOTS I: Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol. Dial. Transplant. (2003) 18(4):819–822.
  • BEKERSKY I, DRESSLER D, MEKKI QA: Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J. Clin. Pharmacol. (2001) 41(2):176–182.
  • EGASHIRA K, FUKUDA E, ONGA T et al. : Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation (2003) 75(7):1057.
  • EGASHIRA K, OHTANI H, ITOH S et al. : Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab. Dispos. (2004) 32(8):828–833.
  • ZIMMERMAN JJ: Exposure-response relationships and drug interactions of sirolimus. AAPS J. (2004) 6(4):e28.
  • ZIMMERMAN JJ, FERRON GM, LIM HK, PARKER V: The effect of a highfat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J. Clin. Pharmacol. (1999) 39(11):1155–1161.
  • KOVARIK JM, HARTMANN S, FIGUEIREDO J et al. : Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. (2002) 22(2):154–159.
  • KOVARIK JM, NOE A, BERTHIER S et al. : Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. J. Clin. Pharmacol. (2003) 43(2):141–147.
  • MORISSETTE P, ALBERT C, BUSQUE S, ST-LOUIS G, VINET B: In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther. Drug Monit. (2001) 23(5):520–525.
  • PESCOVITZ MD, GUASCH A, GASTON R et al. : Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am. J. Transplant. (2003) 3(12):1581–1586.
  • FITZSIMMONS WE, BEKERSKY I, DRESSLER D, RAYE K, HODOSH E, MEKKI Q: Demographic considerations in tacrolimus pharmacokinetics. Transplant. Proc. (1998) 30(4):1359–1364.
  • KOVARIK JM, HSU CH, MCMAHON L, BERTHIER S, RORDORF C: Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin. Pharmacol. Ther. (2001) 70(3):247–254.
  • CHOCAIR PR, DULEY JA, SABBAGA E, ARAP S, SIMMONDS HA, CAMERON JS: Fast and slow methylators: do racial differences influence risk of allograft rejection? J. Med. (1993) 86(6):359–363.
  • WUSK B, KULLAK-UBLICK GA, RAMMERT C, VON ECKARDSTEIN A, FRIED M, RENTSCH KM: Thiopurine Smethyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. Eur. J. Clin. Pharmacol. (2004) 60(1):5–10.
  • LINDHOLM A, WELSH M, ALTON C, KAHAN BD: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin. Pharmacol. Ther. (1992) 52(4):359–371.
  • MIN DI, LEE M KU, YM, FLANIGAN M: Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin. Pharmacol. Ther. (2000) 68(5):478–486.
  • STEIN CM, SADEQUE AJ, MURRAY JJ, WANDEL C, KIM RB, WOOD AJ: Cyclosporine pharmacokinetics and pharmacodynamics in African-American and white subjects. Clin. Pharmacol. Ther. (2001) 69(5):317–323.
  • SHAW LM, KORECKA M, ARADHYE S et al. : Mycophenolic acid area under the curve values in African-American and Caucasian renal transplant patients are comparable. J. Clin. Pharmacol. (2000) 40(6):624–633.
  • NEYLAN JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation (1998) 65(4):515–523.
  • ZHENG H, ZEEVI A, SCHUETZ E et al. : Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. (2004) 44(2):135–140.
  • DIRKS NL, HUTH B, YATES CR, MEIBOHM B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther. (2004) 42(12):701–718.
  • SALMELA KT, KYLLONEN LE: Two decades of experience with cyclosporine in renal transplantation in Helsinki. Transplant. Proc. (2004) 36(2 Suppl.):94S-98S.
  • PERRY I, NEUBERGER J: Immunosuppression: towards a logical approach in liver transplantation. Clin. Exp. Immunol. (2005) 139(1):2–10.
  • POLLARD SG: Pharmacologic monitoring and outcomes of cyclosporine. Transplant. Proc. (2004) 36(2 Suppl.):404S-407S.
  • BOOTS JM, CHRISTIAANS MH, VAN HOOFF JP: Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs (2004) 64(18):2047–2073.
  • THERVET E, LEGENDRE C, BEAUNE P, ANGLICHEAU D: Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics (2005) 6(1):37–47.
  • KOBAYASHI M, SAITOH H, KOBAYASHI M, TADANO K, TAKAHASHI Y, HIRANO T: Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats. J. Pharmacol. Exp. Ther. (2004) 309(3):1029–1035.
  • MACKENZIE PI: Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther. Drug Monit. (2000) 22(1):10–13.
  • PICARD N, RATANASAVANH D, PREMAUD A, LE MEUR Y, MARQUET P: Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos. (2005) 33(1):139–146.
  • CUMMINS CL, JACOBSEN W, CHRISTIANS U, BENET LZ: CYP3A4- transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther. (2004) 308(1):143–155.
  • KIRCHNER GI, MEIER-WIEDENBACH I, MANNS MP: Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. (2004) 43(2):83–95.
  • EL-AZHARY RA: Azathioprine: current status and future considerations. Int. J. Dermatol. (2003) 42(5):335–341.
  • FIREMAN M, DIMARTINI AF, ARMSTRONG SC, COZZA KL: Immunosuppressants. Psychosomatics (2004) 45(4):354–360.
  • TONSHOFF B, HOCKER B, WEBER LT: Steroid withdrawal in pediatric and adult renal transplant recipients. Pediatr. Nephrol. (2005) 20(3):409–417.
  • CANTAROVICH M, BESNER JG, BARKUN JS, ELSTEIN E, LOERTSCHER R: Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin. Transplant. (1998) 12(3):243–249.
  • CANTAROVICH M, BARKUN JS, TCHERVENKOV JI, BESNER JG, ASPESLET L, METRAKOS P: Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation (1998) 66(12):1621–1627.
  • CANTAROVICH M, ELSTEIN E, DE VARENNES B, BARKUN JS: Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation (1999) 68(12):1839–1842.
  • EINECKE G, MAI I, FRITSCHE L et al. : The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol. Dial. Transplant. (2004) 19(1):215–222.
  • MUELLER EA, KOVARIK JM, VAN BREE JB, LISON AE, KUTZ K: Safety and steady-state pharmacokinetics of a new oral formulation of cyclosporin A in renal transplant patients. Transpl. Int. (1994) 7(Suppl. 1):S267-S269.
  • ARMSTRONG VW, OELLERICH M: New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin. Biochem. (2001) 34(1):9–16.
  • KAHAN BD, DUNN J, FITTS C et al. : Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation (1995) 59(4):505–511.
  • KAHAN BD, WELSH M, SCHOENBERG L et al. : Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation (1996) 62(5):599–606.
  • CHOCAIR PR, DULEY JA, SIMMONDS HA, CAMERON JS: The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. (1992) 53(5):1051–1056.
  • WEINSHILBOUM RM, SLADEK SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. (1980) 32(5):651–662.
  • KRYNETSKI EY, SCHUETZ JD, GALPIN AJ, PUI CH, RELLING MV, EVANS WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. USA (1995) 92(4):949–953.
  • OTTERNESS D, SZUMLANSKI C, LENNARD L et al. : Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. (1997) 62(1):60–73.
  • SZUMLANSKI C, OTTERNESS D, HER C et al. : Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. (1996) 15(1):17–30.
  • TAI HL, KRYNETSKI EY, YATES CR et al. : Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. (1996) 58(4):694–702.
  • YATES CR, KRYNETSKI EY, LOENNECHEN T et al. : Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. (1997) 126(8):608–614.
  • SORIA-ROYER C, LEGENDRE C, MIRCHEVA J, PREMEL S, BEAUNE P, KREIS H: Thiopurine-methyl-transferase activity to assess azathioprine myelotoxicity in renal transplant recipients. Lancet (1993) 341(8860):1593–1594.
  • GANIERE-MONTEIL C, PINEAU A, KERGUERIS MF, AZOULAY C, BOURIN M: Thiopurine methyl transferase activity: new extraction conditions for high-performance liquid chromatographic assay. J. Chromatogr. B Biomed. Sci. Appl. (1999) 727(1–2):235–239.
  • SPIRE-VAYRON DE LA MOUREYRE C, DEBUYSERE H, SABBAGH N et al. : Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum. Mutat. (1998) 12(3):177–185.
  • KUEHL P, ZHANG J, LIN Y et al. : Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27(4):383–391.
  • MIN DI, ELLINGROD VL, MARSH S, MCLEOD H: CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. (2004) 26(5):524–528.
  • YATES CR, ZHANG W, SONG P et al. : The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. (2003) 43(6):555–564.
  • GUENGERICH FP: Cytochromes P450, drugs, and diseases. Mol. Interv. (2003) 3(4):194–204.
  • LOWN KS, KOLARS JC, THUMMEL KE et al. : Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. (1994) 22(6):947–955.
  • ANGLICHEAU D, LE CORRE D, LECHATON S et al. : Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. (2005) 5(3):595–603.
  • AMIRIMANI B, NING B, DEITZ AC, WEBER BL, KADLUBAR FF, REBBECK TR: Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. (2003) 42(4):299–305.
  • FLOYD MD, GERVASINI G, MASICA AL et al. : Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics (2003) 13(10):595–606.
  • CHOU FC, TZENG SJ, HUANG JD: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos. (2001) 29(9):1205–1209.
  • TSUCHIYA N, SATOH S, TADA H, LI Z et al. : Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation (2004) 78(8):1182–1187.
  • HESSELINK DA, VAN GELDER T, VAN SCHAIK RH et al. : Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. (2004) 76(6):545–556.
  • HESSELINK DA, VAN SCHAIK RH, VAN DER HEIDEN IP et al. : Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. (2003) 74(3):245–254.
  • VON AHSEN N, RICHTER M, GRUPP C, RINGE B, OELLERICH M, ARMSTRONG VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. (2001) 47(6):1048–1052.
  • MACPHEE IA, FREDERICKS S, MOHAMED M et al. : Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation (2005) 79(4):499–502.
  • THERVET E, ANGLICHEAU D, KING B et al. : Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 76(8):1233–1235.
  • HAUFROID V, MOURAD M, VAN KERCKHOVE V et al. : The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 14(3):147–154.
  • MACKENZIE PI, OWENS IS, BURCHELL B et al. : The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics (1997) 7(4):255–269.
  • WELLS PG, MACKENZIE PI, CHOWDHURY JR et al. : Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. (2004) 32(3):281–290.
  • BULLINGHAM RE, NICHOLLS AJ, KAMM BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. (1998) 34(6):429–455.
  • SHIPKOVA M, ARMSTRONG VW, WIELAND E et al. : Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol. (1999) 126(5):1075–1082.
  • SHIPKOVA M, SCHUTZ E, ARMSTRONG VW, NIEDMANN PD, OELLERICH M, WIELAND E: Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin. Chem. (2000) 46(3):365–372.
  • WIELAND E, SHIPKOVA M, SCHELLHAAS U et al. : Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin. Biochem. (2000) 33(2):107–113.
  • NAWROCKI A, SOLARI S, KANG J, SHAW LM: Mycophenolic Acid. Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2005).
  • VILLENEUVE L, GIRARD H, FORTIER LC, GAGNE JF, GUILLEMETTE C: Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7- ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. (2003) 307(1):117–128.
  • BERNARD O, GUILLEMETTE C: The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. (2004) 32(8):775–778.
  • BHASKER CR, MCKINNON W, STONE A et al. : Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics. (2000) 10(8):679–685.
  • HOLTHE M, KLEPSTAD P, ZAHLSEN K et al.: Morphine glucuronideto- morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. (2002) 58(5):353–356.
  • SHIPKOVA M, ARMSTRONG VW, WEBER L et al. : Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther. Drug Monit. (2002) 24(3):390–399.
  • COURT MH, KRISHNASWAMY S, HAO Q et al. : Evaluation of ’-azido-’- deoxythymidine, morphine, and codeine as probe substrates for UDPglucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos. (2003) 31(9):1125–1133.
  • HOFFMANN U, KROEMER HK: The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev. (2004) 36(3–4):669–701.
  • CHRISTIANS U: Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther. Drug Monit. (2004) 26(2):104–106.
  • CASCORBI I, GERLOFF T, JOHNE A et al. : Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 69(3):169–174.
  • ISHIKAWA T, HIRANO H, ONISHI Y, SAKURAI A, TARUI S: Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab. Pharmacokinet. (2004) 19(1):1–14.
  • JOHNE A, KOPKE K, GERLOFF T et al. : Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. (2002) 72(5):584–594.
  • GOTO M, MASUDA S, SAITO H et al. : C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than P-gp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 12(6):451–457.
  • TANABE M, IEIRI I, NAGATA N et al. : Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297(3):1137–1143.
  • HOFFMEYER S, BURK O, VON RICHTER O et al. : Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97(7):3473–3478.
  • ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P et al. : Association of the multidrug resistance-1 gene singlenucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. (2003) 14(7):1889–1896.
  • BONHOMME-FAIVRE L, DEVOCELLE A, SALIBA F et al.: MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in livertransplant recipients. Transplantation (2004) 78(1):21–25.
  • GERLOFF T, SCHAEFER M, JOHNE A et al. : MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. (2002) 54(6):610–616.
  • SAKAEDA T, NAKAMURA T, HORINOUCHI M et al. : MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. (2001) 18(10):1400–1404.
  • KIM RB, LEAKE BF, CHOO EF et al. : Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 70(2):189–199.
  • SHAW LM, NOWAK I: Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther. Drug Monit. (1995) 17(6):685–689.
  • SUZUKI H, SUGIYAMA Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. (2002) 54(10):1311–1331.
  • ASANO T, NISHIMOTO K, HAYAKAWA M: Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant. Proc. (2004) 36(7):2096–2097.
  • KUSUHARA H, SUGIYAMA Y: Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control. Release. (2002) 78(1–3):43–54.
  • HIROUCHI M, SUZUKI H, ITODA M et al. : Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. (2004) 21(5):742–748.
  • MORIYA Y, NAKAMURA T, HORINOUCHI M et al. : Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. (2002) 25(10):1356–1359.
  • YAMAUCHI A, IEIRI I, KATAOKA Y et al. : Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation (2002) 74(4):571–572.
  • GAO Y, XIONG D, YANG M et al. : Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia (2004) 18(3):513–520.
  • GOTZL M, WALLNER J, GSUR A et al. : MDR1 gene expression in lymphocytes of patients with renal transplants. Nephron. (1995) 69(3):277–280.
  • BECQUEMONT L, CAMUS M, KRIAA F, BARBU V, CHARPENTIER B, JAILLON P: Low levels of lymphocyte MDR1 gene expression during early renal transplantation in patients treated with tacrolimus. Fundam. Clin. Pharmacol. (2000) 14(3):225–229.
  • PARASRAMPURIA DA, LANTZ MV, BIRNBAUM JL, VINCENTI FG, BENET LZ: Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J. Clin. Pharmacol. (2002) 42(3):304–311.
  • ZACHER T, THIELE B, WASSMUTH R, ALBERT FW: Cyclosporine A sensitivity in vitro and P-glycoprotein expression in patients on dialysis and after kidney transplantation. Transpl. Immunol. (2000) 8(2):147–150.
  • HYLE JW, SHAW RJ, REINES D: Functional distinctions between IMP dehydrogenase genes in providing mycophenolate resistance and guanine prototrophy to yeast. J. Biol. Chem. (2003) 278(31):28470–28478.
  • THERVET E, ANGLICHEAU D, LEGENDRE C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. (2001) 22(7):331–337.
  • GLANDER P, HAMBACH P, BRAUN KP et al. : Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. (2004) 4(12):2045–2051.
  • BROGAN IJ, PRAVICA V, HUTCHINSON IV: Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2. Transpl. Immunol. (2000) 8(2):139–141.
  • GUERINI D: Calcineurin: not just a simple protein phosphatase. Biochem. Biophys. Res. Commun. (1997) 235(2):271–275.
  • LIN MJ, PARSIA SS, PAPOLOS DF, LACHMAN HM: Highly polymorphic sequence variation in calcineurin B coding region (PPP3R1). Hum. Mol. Genet. (1994) 3(3):520.
  • SCHULMAN SL, PALMER J, DUNN S, KAISER BA, POLINSKY MS, BALUARTE HJ: Effect of recipient’s race on pediatric renal allograft survival: a singlecenter study. Pediatrics (1992) 89(6 Pt 1):1055–1058.
  • EMOVON OE, KING JA, HOLT CO, SINGLETON B, HOWELL D, BROWNE BJ: Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. Clin. Transplant. (2003) 17(3):206–211.
  • MACPHEE IA, FREDERICKS S, TAI T et al. : The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. (2004) 4(6):914–919.
  • JIRASIRITHAM S, SUMETHKUL V, MAVICHAK V, NA-BANGCHANG K: The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant. Proc. (2004) 36(7):2076–2078.
  • CHRISTIANS U, POKAIYAVANICHKUI T, CHAN L: Tacrolimus. Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2005).
  • JOHNSTON A, HOLT DW: Cyclosporine. Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2005).
  • PIEPER AK, BUHLE F, BAUER S et al. : The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol. Dial. Transplant. (2004) 19(10):2630–2633.
  • MCLAUGHLIN GE, ROSSIQUE-GONZALEZ M, GELMAN B, KATO T: Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. Transplant. Proc. (2000) 32(3):665–668.
  • SCHONDER KS, SHULLO MA, OKUSANYA O: Tacrolimus and lopinavir/ ritonavir interaction in liver transplantation. Ann. Pharmacother. (2003) 37(12):1793–1796.
  • SHEIKH AM, WOLF DC, LEBOVICS E, GOLDBERG R, HOROWITZ HW: Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation (1999) 68(2):307–309.
  • CLAESSON K, BRATTSTROM C, BURKE JT: Sirolimus and erythromycin interaction: two cases. Transplant. Proc. (2001) 33(3):2136.
  • ARONSON J: Serious drug interactions. Practitioner (1993) 237(1531):789–791.
  • CATTANEO D, PERICO N, GASPARI F, GOTTI E, REMUZZI G: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. (2002) 62(3):1060–1067.
  • PODDER H, STEPKOWSKI SM, NAPOLI KL et al. : Pharmacokinetic interactions augment toxicities of sirolimus/ cyclosporine combinations. J. Am. Soc. Nephrol. (2001) 12(5):1059–1071.
  • JUSKO WJ, FERRON GM, MIS SM, KAHAN BD, ZIMMERMAN JJ: Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J. Clin. Pharmacol. (1996) 36(12):1100–1106.
  • PAPE L, FROEDE K, STREHLAU J, EHRICH JH, OFFNER G: Alterations of cyclosporin A metabolism induced by mycophenolate mofetil. Pediatr. Transplant. (2003) 7(4):302–304.
  • ZUCKER K, ROSEN A, TSAROUCHA A et al. : Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl. Immunol. (1997) 5(3):225–232.
  • DEL TACCA M: Prospects for personalized immunosuppression: pharmacologic tools - a review. Transplant. Proc. (2004) 36(3):687–689.
  • BACKMAN L, KREIS H, MORALES JM, WILCZEK H, TAYLOR R, BURKE JT: Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br. J. Clin. Pharmacol. (2002) 54(1):65–68.
  • FLECHNER SM, GOLDFARB D, MODLIN C et al. : Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 74(8):1070–1076.
  • YOKOGAWA K, SHIMADA T, HIGASHI Y et al. : Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem. Pharmacol. (2002) 63(4):777–783.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.